ストックスクリーナーアプリを入手
31.06
0.64%
-0.20
前日終値:
$31.26
開ける：
$31.17
24時間の取引高:
1.69M
Relative Volume:
0.88
時価総額：
$5.13B
収益：
$1.51B
当期純損益:
$333.35M
株価収益率:
15.93
EPS:
1.95
ネットキャッシュフロー:
$315.22M
1週間 パフォーマンス:
+11.37%
1か月 パフォーマンス:
+3.53%
6か月 パフォーマンス:
-1.90%
1年 パフォーマンス:
+9.48%
1日の値動き範囲:
$30.98
$31.68
1週間の範囲:
$27.60
$31.68
52週間の値動き範囲:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
ALKS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
31.06 | 5.16B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
146.42 | 64.92B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.60 | 45.60B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.95 | 39.54B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.01 | 23.00B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
453.07 | 20.06B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2025-06-17 | アップグレード | UBS | Neutral → Buy |
| 2025-05-28 | 開始されました | Needham | Buy |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | アップグレード | UBS | Sell → Neutral |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-11-05 | アップグレード | Stifel | Hold → Buy |
| 2024-06-17 | 開始されました | TD Cowen | Buy |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-20 | ダウングレード | UBS | Neutral → Sell |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 開始されました | UBS | Neutral |
| 2022-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 開始されました | Piper Sandler | Neutral |
| 2022-04-22 | 再開されました | Goldman | Buy |
| 2022-04-20 | 開始されました | Goldman | Buy |
| 2022-01-27 | アップグレード | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 開始されました | Citigroup | Neutral |
| 2021-10-07 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-02 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-10-15 | アップグレード | Mizuho | Neutral → Buy |
| 2020-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2020-02-14 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-01-31 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-31 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-12-19 | ダウングレード | Goldman | Neutral → Sell |
| 2018-12-14 | 開始されました | Wolfe Research | Underperform |
| 2018-12-13 | ダウングレード | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 開始されました | Piper Jaffray | Neutral |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Alkermes Plc (ALKS) 最新ニュース
Is Alkermes plc (8AK) stock cheap vs fundamentalsWeekly Trading Summary & AI Optimized Trade Strategies - newser.com
Is Alkermes plc reversing from oversold territoryJuly 2025 Drop Watch & Accurate Buy Signal Alerts - newser.com
Will Alkermes plc (8AK) stock hit Wall Street targetsVolume Spike & Comprehensive Market Scan Insights - newser.com
Technical analysis overview for Alkermes plc stockMarket Weekly Review & Fast Exit/Entry Strategy Plans - newser.com
Alkermes Plc Experiences Evaluation Revision Amidst Mixed Market Signals and Performance Trends - Markets Mojo
Alkermes sued over alleged scheme to block generic Vivitrol - Reuters
Is Alkermes plc a good long term investmentMACD Trading Signals & Investor Community Interactions - earlytimes.in
Will Alkermes plc (8AK) stock benefit from Fed rate cuts2025 Market Overview & Comprehensive Market Scan Insights - newser.com
Can Alkermes plc stock deliver strong Q4 earningsPortfolio Growth Summary & Fast Gaining Stock Reports - newser.com
How cyclical is Alkermes plc (8AK) stock compared to rivals2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - newser.com
What candlestick patterns are forming on Alkermes plcJuly 2025 Patterns & Fast Gain Stock Trading Tips - newser.com
Is Alkermes plc (8AK) stock at risk of policy regulationRisk Management & Weekly Chart Analysis and Trade Guides - newser.com
Alkermes Plc Hits Day High with Strong 10.58% Intraday Surge - Markets Mojo
Alkermes (ALKS) Added to Wells Fargo's Tactical Ideas List - GuruFocus
What analysts say about Alkermes plc 8AK stockPrice-to-Earnings Ratio Insights & Budget Friendly Capital Growth - earlytimes.in
What drives Alkermes plc stock priceMarket Breadth Indicators & Explosive Profit Trading - earlytimes.in
Alkermes : Corporate Responsability Report - MarketScreener
Alkermes plc (ALKS) Stock Analysis: Exploring a 49.54% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
U.S. Buprenorphine Market Set for Dynamic Growth with Key - openPR.com
How Investors May Respond To Alkermes (ALKS) Phase 2 Alixorexton Narcolepsy Trial Outperformance - Sahm
Alkermes upgraded at RBC Capital Markets ahead of key catalyst - MSN
Is Alkermes' (ALKS) Narcolepsy Drug Breakthrough Shifting Its Investment Narrative? - Yahoo Finance
Alkermes Plc Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says - MarketScreener
Alkermes stock upgraded at RBC Capital Markets (ALKS:NASDAQ) - Seeking Alpha
Alkermes (NASDAQ:ALKS) Shares Gap Up After Analyst Upgrade - MarketBeat
Alkermes (NASDAQ:ALKS) Upgraded by Royal Bank Of Canada to "Outperform" Rating - MarketBeat
RBC Capital Upgrades ALKS: Price Target Raised to $44 | ALKS Sto - GuruFocus
RBC Capital Upgrades Alkermes (ALKS) - Nasdaq
RBC Capital Upgrades Alkermes to Outperform From Sector Perform, Adjusts PT to $44 From $42 - MarketScreener
Assenagon Asset Management S.A. Has $2.40 Million Position in Alkermes plc $ALKS - MarketBeat
Nanotechnology Drug Delivery Market Booming Rapidly - openPR.com
Oliver Luxxe Assets LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat
Alkermes Plc (ALKS) 財務データ
収益
当期純利益
現金流量
EPS
0.83%
9.21%
大文字化:
|
ボリューム (24 時間):